This year was another active one for research and clinical advances.
More than half of the top stories selected by our editorial board focused on prevention strategies. Our top story was on the REDUCE-IT trial, which found that icosapent ethyl reduced cardiovascular risks beyond statins in patients with established cardiovascular disease (CVD) or diabetes. Despite some controversy about the unclear mechanism of action, our Editor said that she would consider using this medication. In contrast, in the CIRT trial, methotrexate in patients with CVD or diabetes or metabolic syndrome failed to reduce risk, perhaps because the drug, surprisingly, did not appear to affect inflammation, as measured by interleukin-1β, interleukin-6, and C-reactive pr…
Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association